uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted March 9, 2021

CBD Seller Warned for Drug and COVID-19 Claims

On March 1, 2021, the FDA issued a warning letter to Cannafyl following a review of the company's website, which found statements made about the company's products Balance CBD Drops, Relief CBD Drops, Relax CBD Drops and Relief CBD Salve to be drug claims. In addition, the products were sold with unsupported claims that they can treat coronavirus (COVID-19).

The FDA has previously stated: "There currently are no vaccines, pills, potions, lotions, lozenges or other prescription or over-the-counter products available to treat or cure coronavirus disease 2019 (COVID-19)."

Cannafyl CBD products were promoted with statements such as "How CBD helps manage Cancer Growth," "CBD FOR HYPERTENSION? Check out this informative article that looks into the benefits of CBD on wellness," and "While researchers continue to explore several ways to fight against COVID-19, some are diving a little deeper to see if cannabis derived CBD could possibly benefit those that are suffering from severe forms of this infection."

See ConsumerLab's answer to the question: What are natural remedies for coronavirus (COVID-19)? Do supplements like zinc, vitamin C, or herbals work?

Also see ConsumerLab's CBD and Hemp Extract Supplements Review for tests of related products.

In addition, the CBD products were found to be misbranded because they do not contain adequate directions for safe use, as required by federal regulations.

For more information, use the link below.

Warning Letter: Cannafyl

See Related Warnings:

FTC Takes Further Action Against Deceptive CBD Claims

FTC Crackdown on Six Deceptive CBD Products

FDA Warns Sellers of Unapproved COVID-19 Tests, CBD Products

Seller of CBD and NAC Warned for Coronavirus Claims

51 CBD Products Recalled Due to Lead Contamination